Key result
Cardiac biomarkers, particularly BNP and NT-proBNP, demonstrated modest to good discrimination for predicting newly detected atrial fibrillation after ischemic stroke or TIA.
Why the study?
Several molecular biomarkers predict newly detected atrial fibrillation, but their identification and predictive performance after an ischaemic stroke or TIA needed evaluation.
Do molecular biomarkers predict newly detected atrial fibrillation in patients with ischemic stroke or TIA?
Systematic Review (n=4,640)
Do molecular biomarkers predict newly detected atrial fibrillation in patients with ischemic stroke or TIA?
Cardiac biomarkers such as BNP and NT-proBNP show modest to good discriminative ability for predicting newly detected atrial fibrillation after ischemic stroke or TIA, potentially aiding in risk stratification for extended ECG monitoring.
Answers are grounded in this paper and cite their sources.
May aid selection for prolonged monitoring after stroke/TIA; confirms BNP/NT-proBNP discrimination in Level 1 synthesis.
Background: Several molecular biomarkers are available that predict newly detected atrial fibrillation (NDAF). We aimed to identify such biomarkers that predict NDAF after an Ischaemic stroke (IS)/Transient Ischaemic Attack (TIA) and evaluate their performance. Methods: A systematic review was undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Studies of patients with IS, TIA, or both, who underwent ECG monitoring for ⩾24 h, which reported molecular biomarkers and frequency of NDAF after electronic searches of multiple databases were included. Results: Twenty-one studies (76% IS, 24% IS and TIA) involving 4640 patients were included. Twelve biomarkers were identified, with cardiac biomarkers evaluated in the majority (75%) of patients. Performance measures were inconsistently reported. Among cohorts selecting high-risk individuals (12 studies), the most studied biomarkers were N-Terminal-Pro Brain Natriuretic Peptide (NT-ProBNP, five studies; C-statistics reported by three studies, 0.69-0.88) and Brain Natriuretic Peptide (BNP, two studies; C-statistics reported in two studies, 0.68-0.77). Among unselected cohorts (nine studies), the most studied biomarker was BNP (six studies; C-statistics reported in five studies, 0.75-0.88). Only BNP was externally validated (two studies) but using different thresholds to categorise risk of NDAF. Conclusion: Cardiac biomarkers appear to have modest to good discrimination for predicting NDAF, although most analyses were limited by small, heterogeneous study populations. Their clinical utility should be explored further, and this review supports the need to assess the role of molecular biomarkers in large prospective studies with standardised selection criteria, definition of clinically significant NDAF and laboratory assays.
No takes yet. Share an insight, caveat, or question.
Ward et al. (2022) conducted a systematic review in Ischaemic stroke or Transient Ischaemic Attack (TIA) (n=4,640). Cardiac molecular biomarkers (BNP and NT-proBNP) vs. Unexposed/lower biomarker levels was evaluated on Newly detected atrial fibrillation (NDAF) (C-statistic 0.68-0.88). Cardiac biomarkers, particularly BNP and NT-proBNP, demonstrated modest to good discrimination for predicting newly detected atrial fibrillation after ischemic stroke or TIA.
Synapse has enriched 10 related papers. Consider them for comparative context: